Phenoxybenzamine Transdermal Composition

Abstract

A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patient's tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications.

Dependencies are inferred from the claim text.